Zostavax patient information sheet

Shingles Vaccine Information Statement. Tell your vaccine provider if the person getting the vaccine: Has had an allergic reaction after a previous dose of live shingles vaccine or varicella vaccine, or has any severe, life-threatening allergies.

One dose of Zostavax ® is indicated for the prevention of shingles. It can be given to patients who have previously had shingles. Since 1 April 2018, one dose of Zostavax is funded for adults aged 65 years. A 'catch-up' programme has been extended to 31 December 2020 for people who were aged 66–80 years inclusively on 1 April 2018.

Jul 08, 2019 · Is there a shingles vaccine? In the UK there is a shingles vaccine immunisation programme for people aged 70 years to protect against herpes zoster. There is also a catch-up programme which offers the vaccine to certain people aged between 70 and 79 years who may have previously missed out on immunisation. Health Information on Shingles: MedlinePlus Multiple Languages Collection. Vaccine Information Statement (VIS) -- Recombinant Zoster (Shingles) Vaccine, RZV: What You Need to Know - English PDF Vaccine Information Statements (VISs) are information sheets produced by the Centers for Disease Control and Prevention (CDC). VISs explain both the benefits and risks of a vaccine to adult vaccine recipients and the parents or legal representatives of vaccinees who are children and adolescents.

For patients and healthcare professionals, the Immunization Action Coalition (IAC) provides zoster (shingles) vaccine information handouts, print materials, and fact sheets. Mar 18, 2019 · Zoster vaccine is usually given as a one-time injection. Unless your doctor tells you otherwise, you will not need a booster vaccine. Read all patient information, medication guides, and instruction sheets provided to you. Ask your doctor or pharmacist if you have any questions. A single dose of shingles vaccine is recommended and funded for adults at 70 years of age. Adults 71-79 years of age are also eligible under a five-year catch up program until 31 October 2021. At the commencement of the program, the interest in the vaccine was unprecedented.